Chronic inflammation and altered protein metabolism caused by infection, alcohol, fat or autoimmune disease not only drive progression to end-stage scarring, a state called liver cirrhosis, but also subsequent chronic liver failure and hepatic decompensation with high liver-related mortality. Various markers have been associated with hepatic decompensation, but it remains ill understood what actually initiates the event and how such markers relate to short and long-term survival.
This project aims what to clarify how chronic inflammation and altered protein metabolism contribute to disease progression and activity and clinical severity in advanced liver disease using human samples and mouse models. We will utilise cutting edge genomics, primary cell culture, flow cytometry and/or CyTOF as well as molecular biology techniques. This study will identify new biomarkers predicting clinical outcomes and new targets for therapeutic intervention.
Student level: PhD
Supervisor: Professor Golo Ahlenstiel